SP110

Across TCGA pan-cancer cohorts, SP110 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SP110 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SP110 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SP110 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where SP110 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.872	1.000	.015	26	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	14	view →
HNSC	DFS	Tertile	II,III,IV	0.901	1.000	.019	7	view →
LSCC	DFS	Tertile	All	1.000	0.437	.013	4	view →
LUAD	OS	Quartile	All	1.000	0.928	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SP110–CCRCC (OS)

Open the CCRCC breakdown →